SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Clanker is an autonomous agent for deploying tokens. Currently, users may request clanker to deploy an ERC-20 token on Base by tagging it @clanker on Farcaster.

tokenbot

Clanker Crypto is trending due to its recent acquisition by Farcaster, a decentralized social network, which the community believes will significantly boost the token's utility and value.  Traders are also focused on the project's tokenomics, specifically its aggressive buyback and burn mechanism, and comparing its market cap to other projects in the space. Some users are reporting issues with trading on Coinbase, while others speculate about upcoming exchange listings.

Hyperliquid is a performant L1 optimized from the ground up. The vision is a fully onchain open financial system with user built applications interfacing with performant native components, all without compromising end user experience. The Hyperliquid L1 is performant enough to operate an entire ecosystem of permissionless financial applications – every order, cancel, trade, and liquidation happens transparently on-chain with block latency <1 second. The chain currently supports 100k orders / second. The Hyperliquid L1 uses a custom consensus algorithm called HyperBFT which is heavily inspired by Hotstuff and its successors. Both the algorithm and networking stack are optimized from the ground up to support the L1. The flagship native application is a fully onchain order book perpetuals exchange, the Hyperliquid DEX. Further developments include a native token standard, spot trading, permissionless liquidity, etc.

Hype

Hype is trending as traders discuss its potential for further upside, with some eyeing new all-time highs. Community members are actively debating entry points and whether to lock in profits, while others promote staking. Some users are calling it "the house of all finance", and the coin is seeing bullish sentiment as a perp DEX.

An AI x Metaverse Protocol that is building the future of virtual interactions.

Virtual Protocol

Virtual Protocol is trending as the community discusses its recent price movements and potential for further gains, with some suggesting it's primed for a bounce and others remaining cautious. Bullish sentiment is fueled by the project's focus on virtual asset utility and AI integration, while some traders are pointing to technical indicators and potential resistance levels. Discussions also highlight the broader context of AI in crypto trading and the rise of AI agents.

American Bitcoin Corp. engages in the management of a bitcoin accumulation platform. It offers exposure to bitcoin through an industry-first business model that integrates scaled self-mining operations with disciplined accumulation strategies. The company was founded by Eric Trump and Donald John Trump Jr. on October 3, 2018 and is headquartered in Miami, FL.

American Bitcoin Corp. - Ordinary Shares - Class A

American Bitcoin Corp.

ABTC is trending as the community discusses its potential connection to Donald Trump and the broader crypto sector. Some traders point to potential dilution and shorting as factors impacting the stock, while others remain bullish, citing the company's association with American Bitcoin and potential future gains. The stock's performance relative to Bitcoin's price movements and other miners is also a key point of discussion.

Hyperion DeFi, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of ophthalmology products. The company offers a piezo-print technology to deliver micro-doses of micro-therapeutics for the eyes. Its products include MicroProst, MicroStat, MicroTears, and MicroPine. The firm is currently focused on the late-stage development of microdosed medications for presbyopia, myopia progression, and mydriasis. The company was founded by Sean Ianchulev on March 12, 2014 and is headquartered in Laguna Hills, CA.

Hyperion DeFi Inc.

$HYPD is trending as investors discuss its relationship with the $HYPE token and potential benefits from the Kinetiq airdrop. Community members are analyzing recent 13F filings showing institutional investment, while others debate the company's current direction and management's effectiveness. Bullish sentiment revolves around the potential for a short squeeze and significant upside due to the company's treasury strategy.

Ouster, Inc. engages in the provision of high resolution digital lidar sensors that offer advanced 3D vision to machinery, vehicles, robots, and fixed infrastructure assets. The company was founded by Angus Pacala and Mark Frichtl on June 30, 2015 and is headquartered in San Francisco, CA.

Ouster Inc - Ordinary Shares - Class A

Ouster ($OUST) is trending as the community discusses its growth potential in the LiDAR and physical AI space, particularly its strategic shift towards software solutions and partnerships. Investors are closely watching upcoming earnings, product roadmap updates, and potential impacts from macroeconomic factors. Bullish sentiment is building, with some anticipating a significant breakout, while others caution about valuation and execution risks.

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include SyndAccess, Revuforj, Niktimvo, and IncyteCARES. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in New York, NY.

Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals is trending due to recent FDA approval of Revuforj for a specific type of leukemia, though discussions also involve a black box warning and how it compares to competitor Kura's drug. The community is weighing the clinical benefits against potential safety concerns and anticipating the impact on market share. Some are also speculating about a potential buyout before 2027.

Kaspa was fair-launched in November 2021 with no pre-mine, zero pre-sale, and no coin allocations, and is 100 percent community-managed. Kaspa aims to be the world's global sequencer for traditional finance and decentralized crypto markets by utilizing proof-of-work and its BlockDAG consensus protocol, GHOSTDAG. Being the world's fastest proof-of-work network, Kaspa combines five properties: (1) hard money principles, (2) Bitcoin's ethos of security-first fundamentals (boasting a security threshold of fifty percent with significant market hashrate), (3) decentralization from rapid block rate mining, (4) block speeds faster than any PoW or PoS network, and (5) smart contract development through based-rollups without fragmented liquidity. Ushering in all five properties, Kaspa is on track to fulfill Satoshi Nakamoto's vision of a digital medium of exchange while also advancing global layer-one sequencing and minuscule confirmation times dominated by internet latency (cf. chapter 6 of the the paper for some initial benchmarks). The Kaspa implementation includes a lot of cool features and subprotocols including Reachability to query the DAG's topology, Block data pruning (with near-future plans for block header pruning), SPV proofs, and later subnetwork support which will make future implementation of layer 2 solutions much easier.

Kaspa

Kaspa is trending as the community eagerly anticipates the Crescendo hardfork, set to occur soon, which promises to enhance the blockchain's speed and efficiency by transitioning to Rust. Community members are closely watching for potential listings on major exchanges following the upgrade, speculating this could significantly boost visibility and adoption. Discussion also highlights Kaspa's technology, including its blockDAG architecture, and the potential for smart contracts and real-world asset tokenization.

Freeport-McMoRan, Inc. engages in the mining of copper, gold, and molybdenum. It operates through the following segments: North America Copper Mines, South America Operations, Indonesia Operations, Molybdenum Mines, Rod and Refining, Atlantic Copper Smelting and Refining, and Corporate and Other. The North America Copper Mines segment operates open-pit copper mines in Morenci, Bagdad, Safford, Sierrita, Miami in Arizona and Chino, and Tyrone in New Mexico. The South America Operations segment includes Cerro Verde in Peru and El Abra in Chile. The Indonesia Operations segment handles the operations of the Grasberg minerals district that produce copper concentrate containing significant quantities of gold and silver. The Molybdenum Mines segment includes the Henderson underground mine and Climax open pit mine, both in Colorado. The Rod and Refining segment consists of copper conversion facilities located in North America and includes a refinery and rod mills. The Atlantic Copper Smelting and Refining segment smelts and refines copper concentrate and markets refined copper and precious metals in slimes. The Corporate and Other segment offers other mining and eliminations, oil and gas operations, and other corporate and elimination items. The company was founded by James R. Moffett on November 10, 1987, and is headquartered in Phoenix, AZ.

Freeport-McMoRan Inc

Freeport-McMoRan is trending due to a mix of factors including better-than-expected Q3 earnings driven by rising copper and gold prices, despite some operational setbacks. The community is discussing the company's Elliott Wave structure and potential for a sustained bullish phase, with some analysts pointing to production issues at the Grasberg mine and possible upside from reversing Biden-era rules on copper smelters.

Western Digital Corp. engages in the development, manufacture, marketing, and sale of data storage devices and solutions. The company was founded by Alvin B. Phillips in 1970 and is headquartered in San Jose, CA.

Western Digital Corp.

Western Digital ($WDC) is trending as investors assess its potential amid AI-driven demand for data storage and a planned separation of its flash and HDD businesses. Community discussions revolve around recent analyst rating changes, price target adjustments, and options activity, with some expressing frustration over management and execution despite positive industry tailwinds. Bullish sentiment highlights AI's increasing need for storage solutions, while bearish views point to potential overvaluation and the company's historical performance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Take the Zacks Approach to Beat the Market: UnitedHealth, Ovid, Micron in Focus

Zacks' winning streak continues as UnitedHealth, Ovid and Micron deliver standout gains across key model portfolios.

XOMA Royalty Corporation (XOMA) and LAVA Therapeutics NV (LVTX) announced on Friday that they have agreed to amend their previous share purchase agreement and lowered the initial cash consideration to be received by LAVA shareholders.As per the <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.xoma.com/news-events/press-releases/detail/487/xoma-royalty-and-lava-therapeutics-announce-amendment-to">amended deal</a>, LAVA shareholders will receive an initial cash payment of $1.04 per share, down from the range of $1.16 to $1.24 initially agreed upon. Shareholders will also receive a contingent value right (CVR) representing the right to certain cash payments, the companies said.This includes the previously announced rights to receive 75% of the net proceeds related to LAVA’s two partnered assets and 75% of any net proceeds from any out-license or sale of LAVA’s unpartnered programs, in addition to a new right to receive up to approximately $0.23 per CVR.LAVA and XOMA Royalty also agreed to amend LAVA’s minimum net-cash closing condition to be $24.5 million, compared to the previous minimum net-cash closing condition of $31.5 million. The amended agreement is in light of the most recent estimates of LAVA’s expected cash balance at closing, among other factors, the companies said. The proposed acquisition is expected to close in the fourth quarter of 2025, as announced previously.LAVA said that it expects to convene a meeting of shareholders to approve matters related to the deal with XOMA Royalty on November 7, after <a href="https://stocktwits.com/news-articles/markets/equity/lava-therapeutics-stock-drops-after-company-cancels-shareholder-meeting/chDD4XlR3BN">postponing</a> it from its previous date of September 30.Last month, LAVA canceled its shareholder meeting to consider and approve matters related to the proposed transaction with XOMA. XOMA first announced that it would acquire LAVA in August.<a href="https://stocktwits.com/symbol/LVTX">LAVA shares</a> fell 3% on Friday afternoon at the time of writing. On Stocktwits, retail sentiment around LVTX stayed within the ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.<figure class="image"><img style="aspect-ratio:588/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_17_at_2_25_55_PM_png_0c5aac6302.webp" alt="LVTX's Sentiment Meter and Message Volume as of 2:26 p.m. ET on Oct. 17, 2025 | Source: Stocktwits" width="588" height="63"><figcaption>LVTX's Sentiment Meter and Message Volume as of 2:26 p.m. ET on Oct. 17, 2025 | Source: Stocktwits</figcaption></figure>While LVTX shares have gained 56% this year, XOMA stock has risen 30%.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/kezar-life-sciences-stock-hit-with-downgrades-price-target-cuts/ch6sK5FR38U">Kezar Life Sciences Stock Hit With Downgrades And Price Target Cuts: Retail Keeps Hopes Alive</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

LAVA Therapeutics Stock Drops After Amended Deal With XOMA Royalty

As per the amended deal, LAVA shareholders will receive an initial cash payment of $1.04 per share, down from the range of $1.16 to $1.24 initially agreed upon.

Equity

As per the amended deal, LAVA shareholders will receive an initial cash payment of $1.04 per share, down from the range of $1.16 to $1.24 initially agreed upon.


Shares of LAVA Therapeutics (LVTX) declined 8% in the pre-market session on Tuesday after the company canceled the Extraordinary General Meeting of shareholders scheduled to occur today.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/09/30/3158434/0/en/LAVA-Therapeutics-to-Move-Extraordinary-General-Meeting-to-Early-November-2025.html">said</a> that it canceled the meeting to consider and approve certain matters related to its proposed transaction with XOMA Royalty Corporation (XOMA). XOMA announced in August that it will acquire LAVA for between $1.16 and $1.24 per share in cash, in addition to a contingent value right per share. The deal is expected to close in the fourth quarter (Q4) of 2025.The company said on Tuesday that it is canceling the meeting to continue discussions with XOMA concerning its estimated cash forecast and the consideration payable to the company’s shareholders in the transaction.LAVA also noted that both parties remain committed to completing the transaction by the fourth quarter.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/LVTX">LVTX stock</a> rose from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.“We are committed to closing this transaction and look forward to working collaboratively with the LAVA team to further define LAVA’s cash forecast in an effort to close this transaction in an expeditious manner,” said XOMA CEO Owen Hughes.LAVA said on Tuesday that it expects to reconvene the shareholder meeting by early November. The date will be ascertained at a later date, and shareholders who have voted will have to cast their votes again on the matters proposed, it added.LVTX stock is up 69% this year but down approximately 3% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/cryptocurrency/chainlink-swift-advance-blockchain-integration-for-ubs-tokenized-funds/chDD4dRR3Bj">Chainlink, Swift Advance Blockchain Integration For UBS Tokenized Funds</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

LAVA Therapeutics Stock Slips 9% Pre-Market – Here’s Why The Company Canceled Its Shareholder Meeting

The firm stated it canceled the meeting to consider and approve certain matters related to its proposed transaction with XOMA Royalty Corporation. 

Does XOMA Royalty (XOMA) Have the Potential to Rally 85.34% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 85.3% in XOMA Royalty (XOMA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Predict an 86.05% Upside in XOMA Royalty (XOMA): Here's  What You Should Know

The mean of analysts' price targets for XOMA Royalty (XOMA) points to an 86.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Here's Why XOMA Royalty (XOMA) Is a Great 'Buy the Bottom' Stock Now

After losing some value lately, a hammer chart pattern has been formed for XOMA Royalty (XOMA), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Mural Oncology PLC (MURA) and XOMA Royalty Corporation (XOMA) announced on Wednesday that they have entered into a definitive agreement under which a unit of XOMA will acquire Mural for cash.Under the <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.muraloncology.com/news-releases/news-release-details/mural-oncology-announces-entry-agreement-be-acquired-xra-5-corp">deal</a>, each Mural Shareholder would receive a cash price of between $2.035 and $2.24 per share. The base cash price represents a premium of approximately 13.1% to Mural’s closing share price of $1.80 on Tuesday. The additional price per share of up to $0.205 will be paid if Mural’s closing net cash exceeds estimates.MURA stock jumped 14% in the premarket session at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/MURA">Mural</a> jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘high’ levels. Meanwhile, retail sentiment around <a href="https://stocktwits.com/symbol/XOMA">XOMA</a> fell from ‘bullish’ to ‘neutral’ territory over the past 24 hours.Mural's board of directors said that they have determined the acquisition and cash offer by XOMA, a biotechnology royalty aggregator, is in the best interest of all Mural shareholders. The board approved the acquisition and recommended that Mural shareholders vote in favor.The acquisition will be subject to the satisfaction of closing conditions, including approval by Mural shareholders. Excluding additional price per share, the deal values Mural at about $36.2 million.Mural Oncology announced plans to explore strategic alternatives in April after discontinuing all clinical development of Nemvaleukin. The decision followed data from a late-stage trial where Nemvaleukin in combination with Pembrolizumab did not achieve the primary endpoint of a statistically significant improvement in overall survival versus chemotherapy in platinum-resistant ovarian cancer. The company also saw no positive results from a mid-stage study of the drug in mucosal and cutaneous melanoma.MURA stock is down by 44% this year and over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-freezes-hiring-to-cut-costs-says-report/chsinAURdhO">Novo Nordisk Freezes Hiring To Cut Costs, Says Report: Retail Sees Stock Surpassing $100-Mark In A Year</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Mural Oncology To Be Acquired By XOMA Royalty

The Mural board of directors said that they have determined the acquisition and cash offer by XOMA is in the best interest of all its shareholders. 

How Much Upside is Left in XOMA Royalty (XOMA)? Wall Street Analysts Think 106.15%

The average of price targets set by Wall Street analysts indicates a potential upside of 106.2% in XOMA Royalty (XOMA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

XOMA Royalty (XOMA) Q2 Earnings and Revenues Surpass Estimates

XOMA Royalty (XOMA) delivered earnings and revenue surprises of +500.00% and +39.30%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

PTC Therapeutics (PTCT) Reports Q2 Loss, Beats Revenue Estimates

PTC Therapeutics (PTCT) delivered earnings and revenue surprises of +22.43% and +4.82%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

XOMA Royalty Corp. operates as a biotech royalty aggregator, which engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with various assets that provides right to future potential royalty and milestone payments. The company was founded by Patrick J. Scannon in 1981 and is headquartered in Emeryville, CA.

XOMA Royalty Corp.

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

XOMA
XOMA Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest XOMA News

XOMAXOMA Corp